CT/NG Testing Market size was valued at USD 1.60 billion in 2024 and is expected to reach USD 2.67 billion by 2032, growing at a CAGR of 6.62% over the forecast period of 2025-2032.
The CT/NG testing market is growing steadily because of the increasing prevalence of sexually transmitted infections (STIs), growing awareness among patients, and expanding screening programs. Nucleic acid amplification tests (NAATs) have been found to improve the early identification and treatment of these cases, along with the increasing use of point-of-care diagnostics. Rising Self-Testing and Government-Supported Screening Programs Increasing CT/NG testing market growth.
The U.S. CT/NG testing market size was valued at USD 0.43 billion in 2024 and is expected to reach USD 0.80 billion by 2032, growing at a CAGR of 6.08% over the forecast period of 2025-2032. North America CT/NG testing market share for the U.S. is high owing to high volume testing, a well-developed diagnostic infrastructure, along public health programs. Active STI surveillance and national screening programs are contributing to an increase in early detection and diffusion of testing within medical practice.
Chlamydia and gonorrhea are also the first and second most commonly reported STIs in the US, with approximately 1.6 million cases of chlamydia and 601,319 cases of gonorrhea in 2023, respectively.
Drivers
The Growing Incidence of STIs is Boosting the Market Expansion
Increased incidence rates of sexually transmitted infections globally, particularly for Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG), are a key factor fueling demand in the CT/NG testing market. Due to many shifting sexual practices, ignorance, and inadequate preventive measures, they all add up to a higher incidence of disease. Many cases of these infections remain undiagnosed because they often do not cause any symptoms, or the symptoms are mild; however, these infections can lead to serious complications, such as infertility, pelvic inflammatory disease, and increased risk of human immunodeficiency virus (HIV) acquisition and transmission. The increasing burden of these diseases results in high demand for accurate, early diagnostic testing to allow treatment before the wider spread of the disease.
Globally in 2020, among people aged 15 to 49 years, more than 374 million new infections with curable sexually transmitted infections (STIs) were recorded each year, with Chlamydia trachomatis and Neisseria gonorrhoeae as two examples.
Based on data from 188 studies, a global meta-analysis published in 2024 estimated the pooled prevalence of gonorrhea among adults aged 15 to 49 was 7.2% and chlamydia at 9.9%.
Government Initiatives and Screening Programs are Benefiting the Market to Grow
Public health organisations and governments are currently working on strategies to initiate control over the transmission of STIs by introducing routine screening and early diagnosis. For instance, the CDC's National Chlamydia Screening Program in the United States offers grants and guidelines for testing and campaigns to promote testing among high-risk populations, including sexually active young adults. Hence, these efforts supplement the volume of tests and offer new technologies for adoption in diagnosis, thereby contributing to the growth of the CT/NG testing market. The public health policies emphasizing STI control also allow for optimal resource utilization and infrastructure at all levels for the provision of testing facilities.
CDC advocates for STI prevention funding and guidelines, including the National Chlamydia Screening Program, which has been especially effective in increasing the proportion of young people tested.
According to the National Committee for Quality Assurance (NCQA), annual chlamydia screening rates for women ages 16–24 who are sexually active have increased dramatically among commercial HMOs since 2001, growing by 111% by 2023.
Restraint
Fewer Awareness and Stigma are Hampering the Market Expansion
The stigma surrounding STIs (sexually transmitted infections diagnostics) discourages many people from being tested for CT and NG infections. STIs are taboo in many cultures, which creates stigma, embarrassment, and in some cases, fear of being judged. Such stigma prevents people from getting tested and treated, even when they have symptoms or are knowingly at high risk of infection. Moreover, poor sexual health education contributes to not knowing about screening in the first place, which this valid in young adults and the present high-risk population. All of these factors lead to underdiagnosis and underreporting, and combined, they limit the growth factors of the market as they reduce the overall demand for the CT/NG testing services.
By Product Type
The Assays & Kits segment dominated the CT/NG testing market share with an 84.11% market share in 2024, owing to their importance in the accurate and rapid detection of infections. Since the kits offer high sensitivity and specificity, they are the most common type of kit that is used in various kinds of healthcare settings, otherwise diagnostic laboratories otherwise applied point-of-care sites. Molecular diagnostics have paved new avenues with their rapidity, ability to interface with various testing platforms, and multiplex assay systems for simultaneous diagnosis of both Chlamydia trachomatis and Neisseria gonorrhoeae, thus establishing them as the gold standards for large-scale screening programs and routine diagnostics globally.
The Instruments/Analyzers segment is expected to register the fastest growth throughout the forecasting period, due to the technological innovations and increased use of automated and high-throughput testing platforms. Modern analyzers increase the efficiency of testing by reducing the overall turnaround time and decreasing the chances of human error, playing a key role in handling rising volumes of tests. In addition, the high demand for POC and decentralized testing solutions is further stimulating the investments for miniaturized, portable instruments that can gain rapid and reliable results, thus propelling this segment's growth.
By Test Type
The laboratory testing segment dominated the CT/NG testing market with an 89.5% market share in 2024, due to accuracy, reliability, and sample volume handling. Although such methods are more demanding and require trained personnel, modern NAATs, which have become the mainstream in centralized laboratories, provide very sensitive and specific results and, due to their advantages of more reliable detection, are generally considered key for confirmatory diagnosis and applicable in routine screening programs. It also ensures quality control and full reporting through already established infrastructure and trained manpower in laboratories to facilitate its widespread application in hospitals and diagnostic centers.
The fastest-growing segment is predicted to be Point-of-Care (POC) Testing, owing to the rising need for rapid on-site diagnostics. POC tests have the benefit of rapid turnaround times, leading to early clinical decision-making and antimicrobial initiation, particularly valuable in resource-limited and remote locations. POC tests adoption is driven by increasing awareness towards sexual health, convenience, and decentralization of healthcare models, and growing advancements in technology, making POC tests more accurate for ease of use, in turn fueling market growth.
By Technology
The PCR segment dominated the CT/NG testing market with a 68.06% market share in 2024 due to the high sensitivity, specificity, and high adoption rate of PCR-based tests as a gold standard for Chlamydia trachomatis and Neisseria gonorrhoeae infections. The PCR technology, being highly specific, can amplify even in small quantities the genetic material that is specific for a particular organism, and thus, early and almost accurate diagnosis can be made for very low bacterial load, having the same genetic material for amplification. PCR's established role in clinical laboratories, multiplex testing options, and strong regulatory approvals have positioned it as the global preferred method for large-scale screening and confirmatory testing.
The isothermal nucleic acid amplification technology segment is anticipated to experience the fastest growth through the forecast period, owing to rapid, cheap, and easy alternatives to conventional PCR. Their work isothermally at a constant temperature, thus not requiring expensive thermal cyclers, making them suitable for point-of-care and resource-limited settings. The increasing need for rapid turnaround times, portable devices, and point-of-use testing has helped propel isothermal amplification for significant growth in the CT/NG testing space.
By End-use
The 2024 CT/NG testing market, dominated by the diagnostic laboratories segment with a 56.8% market share in 2024, due to a unique infrastructure that is beneficial when conducting simplex & multiplex CT/NG tests, along with increased capacity for testing and higher expertise in complex molecular diagnostics. Such laboratories are situated in a central configuration and can process thousands of samples by automated nucleic acid amplification tests (NAATs) to yield accurate results. As such, their capacity to underpin population screening programs and liaise with public health authorities renders them a key pillar in the detection and management of CT and NG.
During the forecast period, the hospitals & clinics segment is expected to record the fastest growth due to the rising incorporation of on-site testing & rapid diagnostics in clinical laboratories. It is important in treating STIs that hospitals expand their facilities to offer immediate testing and that patients get immediate results and diagnosis. Moreover, the increasing outpatient clinic population, increasing promotional awareness towards sexual health, and growing expenditures in healthcare infrastructure are making a significant contribution to the adoption of CT/NG testing services in hospitals and clinics, thereby rapidly driving the market growth.
The CT/NG testing market is dominated in North America with a 38.60% market share in 2024, due to strong healthcare systems, higher inclination toward STI awareness, and solid routine screening programs. Some of these emerging trends are also driven by government efforts, including STI prevention strategies promoted by the Centers for Disease Control and Prevention (CDC), which advocate testing and prompt detection, especially among high-risk populations. In addition, the increasingly fast adoption of molecular diagnostic technologies such as nucleic acid amplification tests (NAATs) and the well-established reimbursement policies to ensure patient access to testing also favour the region.
The CT/NG testing market in Asia Pacific is projected to be the fastest-growing region with a 7.45% CAGR over the forecast years due to the rising prevalence of STIs, improving access to healthcare, and increasing awareness about sexual health. The increasing disease burden due to urbanization, shifting sexual behavior and poorer early detection has led to governments strengthening diagnostic capabilities. Increasing investments in public health infrastructure and affordability of testing (including rapid point-of-care diagnostics, particularly in China, India, and Southeast Asian countries) will also be seen as positive developments in the region.
The CT/NG testing market in Europe is growing at a lucrative rate, due to the presence of strong public health policies and comprehensive screening programs. National programs or initiatives, as seen in the UK, for instance, with a National Chlamydia and Gonorrhea Screening Program, have already significantly increased re-testing and early diagnosis. European governments are also increasing sexual health infrastructure and education to help curb the spread of sexually transmitted infections (STIs. Quality diagnostic standards harmonized at the EU level through effective regulatory frameworks can further facilitate the expansion of this market and the uptake of enhanced testing technologies.
Latin America has boosted investments in STI diagnostics, a trend that continues to grow steadily. The lack of infrastructure and the fragmented regulation between nations prevent rapid growth from occurring, creating constant but slow momentum. Public health campaigns are promoting awareness and demand for testing in urban areas, targeting young and at-risk populations. Access remains a challenge, particularly in funded communities and among rural and high-need communities, where diagnostic access is often out of reach.
MEA is experiencing moderate growth in the CT/NG testing market due to Governments in MEA having been introducing tiered CT/NG screening alongside wider public health initiatives. However, the lack of overall health systems and the delayed adoption of advanced diagnostics are limiting growth to a more regional level compared to other regions. Expansion of testing services in high-prevalence areas is being facilitated by international aid programs and NGO Support. Nevertheless, sociocultural constraints and STI stigma in some countries are limiting the reach of screening and education.
Abbott Laboratories, Becton, Dickinson & Company (BD), Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Siemens Healthineers AG, Bio-Rad Laboratories, Inc., Binx Health, and other players.
January 2024 – Qiagen N.V. was FDA cleared for its NeuMoDx CT/NG Assay 2.0, which is intended to enhance sexually transmitted infection (STI) testing, especially Chlamydia trachomatis and Neisseria gonorrhoeae. The assay is for use on Qiagen's NeuMoDx 96 and 288 integrated PCR-based clinical molecular testing systems. It is designed to enhance testing accessibility, cost, and result turnaround time.
October 2022 – Bio-Rad Laboratories introduced two new Exact Diagnostics molecular controls: the CT/NG Positive Run Control and the STI Negative Run Control. These quality controls are applied with molecular assays for the detection of Chlamydia trachomatis and Neisseria gonorrhoeae. They aid test accuracy by checking for possible contamination and sample adequacy and are intended to measure intra- and inter-run laboratory performance.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 1.60 Billion |
| Market Size by 2032 | USD 2.67 Billion |
| CAGR | CAGR of 6.62% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Product Type (Assays & Kits, Instruments/Analyzers) • By Test Type (Laboratory Testing, Point-of-Care (POC) Testing) • By Technology (Isothermal Nucleic Acid Amplification Technology, Polymerase Chain Reaction, Immunodiagnostics, Other Technologies) • By End-use (Hospitals & Clinics, Diagnostic Laboratories, Home Care Setting, Other End-users) |
| Regional Analysis/Coverage | North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Abbott Laboratories, Becton, Dickinson & Company (BD), Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Thermo Fisher Scientific, Inc., Qiagen N.V., Siemens Healthineers AG, Bio-Rad Laboratories, Inc., Binx Health, and other players. |
Ans: The CT/NG Testing Market is expected to grow at a CAGR of 6.62% from 2025 to 2032.
Ans: The CT/NG Testing Market was USD 1.60 billion in 2024 and is expected to reach USD 2.67 billion by 2032.
Ans: Government initiatives and screening programs are benefiting the market, to grow.
Ans: The “Assays & kits” segment dominated the CT/NG Testing Market.
Ans: North America dominated the CT/NG Testing Market in 2024.
Table Of Contents:
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2024)
5.2 Diagnostic Modality Adoption Trends (2020–2024)
5.3 Public Health Program Coverage & Screening Guidelines (2024)
5.4 Prescription and Reimbursement Trends, by Region (2024)
5.5 Healthcare Spending on CT/NG Testing, by Region (2024)
6. Competitive Landscape
6.1 List of Major Companies By Region
6.2 Market Share Analysis By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. CT/NG Testing Market Segmentation By Product Type
7.1 Chapter Overview
7.2 Assays & kits
7.2.1 Assays & kits Market Trends Analysis (2021-2032)
7.2.2 Assays & kits Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Instruments/Analyzers
7.3.1 Instruments/Analyzers Market Trends Analysis (2021-2032)
7.3.2 Instruments/Analyzers Market Size Estimates and Forecasts to 2032 (USD Billion)
8. CT/NG Testing Market Segmentation By Test Type
8.1 Chapter Overview
8.2 Laboratory testing
8.2.1 Laboratory testing Market Trends Analysis (2021-2032)
8.2.2 Laboratory testing Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Point-of-care (POC) testing
8.3.1 Point-of-care (POC) testing Market Trends Analysis (2021-2032)
8.3.2 Point-of-care (POC) testing Market Size Estimates and Forecasts to 2032 (USD Billion)
9. CT/NG Testing Market Segmentation By Technology
9.1 Chapter Overview
9.2 Isothermal nucleic acid amplification technology
9.2.1 Isothermal nucleic acid amplification technology Market Trends Analysis (2021-2032)
9.2.2 Isothermal nucleic acid amplification technology Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Polymerase chain reaction
9.3.1 Polymerase chain reaction Market Trends Analysis (2021-2032)
9.3.2 Polymerase chain reaction Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Immunodiagnostics
9.4.1 Immunodiagnostics Market Trends Analysis (2021-2032)
9.4.2 Immunodiagnostics Market Size Estimates and Forecasts to 2032 (USD Billion)
9.5 Other technologies
9.5.1 Other technologies Market Trends Analysis (2021-2032)
9.5.2 Other technologies Market Size Estimates and Forecasts to 2032 (USD Billion)
10. CT/NG Testing Market Segmentation by End-User
10.1 Chapter Overview
10.2 Hospitals & clinics
10.2.1 Hospitals & clinics Market Trends Analysis (2021-2032)
10.2.2 Hospitals & clinics Market Size Estimates and Forecasts to 2032 (USD Billion)
10.3 Diagnostic laboratories
10.3.1 Diagnostic laboratories Market Trend Analysis (2021-2032)
10.3.2 Diagnostic laboratories Market Size Estimates and Forecasts to 2032 (USD Billion)
10.4 Home care setting
10.4.1 Home care setting Market Trends Analysis (2021-2032)
10.4.2 Home care setting Market Size Estimates and Forecasts to 2032 (USD Billion)
10.5 Other end-users
10.5.1 Other end-users Market Trends Analysis (2021-2032)
10.5.2 Other end-users Market Size Estimates and Forecasts to 2032 (USD Billion)
11. Regional Analysis
11.1 Chapter Overview
11.2 North America
11.2.1 Trend Analysis
11.2.2 North America CT/NG Testing Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.2.3 North America CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.2.4 North America CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.2.5 North America CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.2.6 North America CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.2.7 USA
11.2.7.1 USA CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.2.7.2 USA CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.2.7.3 USA CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.2.7.4 USA CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.2.8 Canada
11.2.8.1 Canada CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.2.8.2 Canada CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.2.8.3 Canada CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.2.8.4 Canada CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.2.9 Mexico
11.2.9.1 Mexico CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.2.9.2 Mexico CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.2.9.3 Mexico CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.2.9.4 Mexico CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3 Europe
11.3.1 Trend Analysis
11.3.2 Europe CT/NG Testing Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.3.3 Europe CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.3.4 Europe CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.3.5 Europe CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.3.6 Europe CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.7 Germany
11.3.7.1 Germany CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.3.7.2 Germany CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.3.7.3 Germany CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.3.7.4 Germany CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.8 France
11.3.8.1 France CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.3.8.2 France CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.3.8.3 France CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.3.8.4 France CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.9 UK
11.3.9.1 UK CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.3.9.2 UK CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.3.9.3 UK CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.3.9.4 UK CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.10 Italy
11.3.10.1 ItalyCT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.3.10.2 Italy CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.3.10.3 Italy CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.3.10.4 Italy CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.11 Spain
11.3.11.1 Spain CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.3.11.2 Spain CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.3.11.3 Spain CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.3.11.4 Spain CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.12 Poland
11.3.12.1 Poland CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.3.12.2 Poland CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.3.12.3 Poland CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.3.12.4 Poland CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.13 Turkey
11.3.13.1 Turkey CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.3.13.2 Turkey CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.3.13.3 Turkey CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.3.13.4 Turkey CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.3.14 Rest of Europe
11.3.14.1 Rest of Europe CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.3.14.2 Rest of Europe CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.3.14.3 Rest of Europe CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.3.14.4 Rest of Europe CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4 Asia Pacific
11.4.1 Trend Analysis
11.4.2 Asia Pacific CT/NG Testing Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.4.3 Asia Pacific CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.4.4 Asia Pacific CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.4.5 Asia Pacific CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.4.6 Asia Pacific CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.7 China
11.4.7.1 China CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.4.7.2 China CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.4.7.3 China CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.4.7.4 China CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.8 India
11.4.8.1 India CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.4.8.2 India CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.4.8.3 India CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.4.8.4 India CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.9 Japan
11.4.9.1 Japan CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.4.9.2 Japan CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.4.9.3 Japan CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.4.9.4 Japan CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.10 South Korea
11.4.10.1 South Korea CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.4.10.2 South Korea CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.4.10.3 South Korea CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.4.10.4 South Korea CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.11 Singapore
11.4.11.1 Singapore CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.4.11.2 Singapore CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.4.11.3 Singapore CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.4.11.4 Singapore CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.12 Australia
11.4.12.1 Australia CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.4.12.2 Australia CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.4.12.3 Australia CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.4.12.4 Australia CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.4.13 Rest of Asia Pacific
11.4.13.1 Rest of Asia Pacific CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.4.13.2 Rest of Asia Pacific CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.4.13.3 Rest of Asia Pacific CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.4.13.4 Rest of Asia Pacific CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5 Middle East and Africa
11.5.1 Trend Analysis
11.5.2 Middle East and Africa CT/NG Testing Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.5.3 Middle East and Africa CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.5.4 Middle East and Africa CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.5.5 Middle East and Africa CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.5.6 Middle East and Africa CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.7 UAE
11.5.7.1 UAE CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.5.7.2 UAE CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.5.7.3 UAE CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.5.7.4 UAE CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.8 Saudi Arabia
11.5.8.1 Saudi Arabia CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.5.8.2 Saudi Arabia CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.5.8.3 Saudi Arabia CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.5.8.4 Saudi Arabia CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.9 Qatar
11.5.9.1 Qatar CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.5.9.2 Qatar CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.5.9.3 Qatar CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.5.1.9.4 Qatar CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.10 South Africa
11.5.10.1 South Africa CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.5.10.2 South Africa CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.5.10.3 South Africa CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.5.10.4 South Africa CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.5.11 Rest of Middle East & Africa
11.5.11.1 Rest of Middle East & Africa CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.5.11.2 Rest of Middle East & Africa CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.5.11.3 Rest of Middle East & Africa CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.5.11.4 Rest of Middle East & Africa CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.6 Latin America
11.6.1 Trend Analysis
11.6.2 Latin America CT/NG Testing Market Estimates and Forecasts by Country (2021-2032) (USD Billion)
11.6.3 Latin America CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.6.4 Latin America CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.6.5 Latin America CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.6.6 Latin America CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.6.7 Brazil
11.6.7.1 Brazil CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.6.7.2 Brazil CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.6.7.3 Brazil CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.6.7.4 Brazil CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.6.8 Argentina
11.6.8.1 Argentina CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.6.8.2 Argentina CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.6.8.3 Argentina CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.6.8.4 Argentina CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
11.6.9 Rest of Latin America
11.6.9.1 Rest of Latin America CT/NG Testing Market Estimates and Forecasts by Product Type (2021-2032) (USD Billion)
11.6.9.2 Rest of Latin America CT/NG Testing Market Estimates and Forecasts by Test Type (2021-2032) (USD Billion)
11.6.9.3 Rest of Latin America CT/NG Testing Market Estimates and Forecasts by Technology Mode (2021-2032) (USD Billion)
11.6.9.4 Rest of Latin America CT/NG Testing Market Estimates and Forecasts by End-User (2021-2032) (USD Billion)
12. Company Profiles
12.1 Abbott Laboratories
12.1.1 Company Overview
12.1.2 Financial
12.1.3 Products/ Services Offered
12.1.4 SWOT Analysis
12.2 Becton, Dickinson & Company (BD)
12.2.1 Company Overview
12.2.2 Financial
12.2.3 Products/ Services Offered
12.2.4 SWOT Analysis
12.3 Danaher Corporation
12.3.1 Company Overview
12.3.2 Financial
12.3.3 Products/ Services Offered
12.3.4 SWOT Analysis
12.4 F. Hoffmann-La Roche Ltd.
12.4.1 Company Overview
12.4.2 Financial
12.4.3 Products/ Services Offered
12.4.4 SWOT Analysis
12.5 Hologic, Inc.,
12.5.1 Company Overview
12.5.2 Financial
12.5.3 Products/ Services Offered
12.5.4 SWOT Analysis
12.6 Thermo Fisher Scientific
12.6.1 Company Overview
12.6.2 Financial
12.6.3 Products/ Services Offered
12.6.4 SWOT Analysis
12.7 Qiagen N.V.,
12.7.1 Company Overview
12.7.2 Financial
12.7.3 Products/ Services Offered
12.7.4 SWOT Analysis
12.8 Siemens Healthineers AG
12.8.1 Company Overview
12.8.2 Financial
12.8.3 Products/ Services Offered
12.8.4 SWOT Analysis
12.9 Bio-Rad Laboratories,
12.9.1 Company Overview
12.9.2 Financial
12.9.3 Products/ Services Offered
12.9.4 SWOT Analysis
12.10 Binx Health
12.10.1 Company Overview
12.10.2 Financial
12.10.3 Products/ Services Offered
12.10.4 SWOT Analysis
13. Use Cases and Best Practices
14. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments:
By Product Type
By Test Type
By Technology
By End-use
Request for Segment Customization as per your Business Requirement: https://www.snsinsider.com/sample-request/7454
Regional Coverage:
North America
Europe
Asia Pacific
Middle East & Africa
Latin America
Request for Country Level Research Report: https://www.snsinsider.com/sample-request/7454
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report: